MorphoSys Announces Expansion of Antibody Alliance

MorphoSys Announces Expansion of Antibody Alliance 
MARTINSRIED, GERMANY and MUNICH, GERMANY -- (Marketwire) -- 11/07/12
--  
Collaboration to Benefit from Access to Newest Technologies 
MorphoSys  AG  (FSE: MOR;  Prime  Standard  Segment, TecDAX)
announced today an expansion  of its strategic alliance with 
Novartis. The long-term alliance will
now  benefit  from  new 
technologies  that  were not available when the current
agreement
between the two companies was signed in 2007. The aim is to
accelerate
the  discovery  of  new  therapeutic  antibodies  and  to 
increase  the overall
productivity of the collaboration. Financial
details were not disclosed. 
"Today's announcement marks the commercial launch of our new
technology platform
Ylanthia", commented Dr. Simon Moroney, Chief
Executive Officer of MorphoSys AG. "We are delighted to kick off this
new phase in our growth as the premier source
of  therapeutic
antibodies with our biggest  partner, Novartis. This alliance is very
 successful and  will continue  to contribute  significantly to our
overall
pipeline  of therapeutic  antibodies. I'm  confident that  by
adding  the newest
technologies  to our collaboration, we can  be
even more productive. The benefit
will   be  better  therapeutic 
antibodies,  made  faster  than  was previously
possible." 
"We  are  pleased  to  expand  our  relationship with MorphoSys,"
commented Mark
Fishman, President of the Novartis Institutes for
BioMedical Research. "A number
of  programs  have  emerged  from  the
 collaboration  so far, and we're looking
forward  to adding to them
in the years ahead. Novartis is committed to bringing
innovative 
antibody-based  therapies  to  market  and  the  collaboration
with
MorphoSys is a key part of that effort." 
Under  the terms of the agreement announced  today, the companies
will apply the entire  suite of new technologies available to
MorphoSys, including Ylanthia and Slonomics,  to  make  therapeutic 
antibodies.  It  is  expected  that the next-generation  Ylanthia 
platform  will  follow  HuCAL,  which  is  the technology
currently 
used  by  the  partners  to  source  therapeutic antibody
candidates.
Antibody   optimization   will   use   Slonomics-based 
technology  for precise
optimization  of  antibody  properties.  The 
companies  will also cross- license
future  improvements for their
mutual benefit.  Novartis will continue to fund a dedicated  research
team at MorphoSys and  pay annual license fees as previously
until 
the end of the  collaboration in 2017. The companies  agreed to waive
the existing co-development options, as MorphoSys looks to increase
its focus on its own highly promising proprietary portfolio of
therapeutic antibody  candidates. 
MorphoSys  and Novartis started working  together in 2004. In
December 2007, the two  companies substantially extended  their
relationship and  forged one of the most  comprehensive  strategic 
alliances  in  the  discovery and development of biopharmaceuticals. 
The collaboration has resulted  in six clinical programs to date,
with four currently being evaluated in phase 2. 
About MorphoSys: 
MorphoSys developed HuCAL, the most successful antibody library
technology in
the pharmaceutical industry. By successfully applying
this and other patented
technologies, MorphoSys has become a leader
in the field of therapeutic antibodies, one of the fastest-growing
drug classes in human healthcare. The
company's AbD Serotec unit uses
HuCAL and other antibody technologies to generate superior monoclonal
antibodies for research and diagnostic applications. 
Together with its pharmaceutical partners, MorphoSys has built a
therapeutic
pipeline of more than 70 human antibody drug candidates
for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's
disease, to name just a few. With
its ongoing commitment to new
antibody technology and drug development, MorphoSys is focused on
making the healthcare products of tomorrow. MorphoSys is listed on
the Frankfurt Stock Exchange under the symbol MOR. For regular
updates
about MorphoSys, visit http://www.morphosys.com 
HuCAL(R),  HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R),
RapMAT(R), arYla(R), Ylanthia(R)  and  100 billion  high 
potentials(R)  are registered trademarks of MorphoSys AG 
Slonomics(R)  is  a  registered  trademark  of  Sloning 
BioTechnology GmbH,  a subsidiary of MorphoSys AG. 
This  communication contains  certain forward-looking  statements
concerning the MorphoSys  group of  companies. The  forward-looking
statements contained herein
represent  the judgment of MorphoSys as
of  the date of this release and involve
risks  and  uncertainties. 
Should  actual  conditions differ from the Company's
assumptions, 
actual  results  and  actions  may  differ from those
anticipated.
MorphoSys  does not intend to update  any of these
forward-looking statements as far as the wording of the relevant press
release is concerned. 
Media Release (PDF): http://hugin.info/130295/R/1655601/535006.pdf 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
that: 
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: MorphoSys AG via Thomson Reuters ONE 
[HUG#1655601] 
For more information, please contact: 
MorphoSys AG
Dr. Claudia Gutjahr-Loser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122 
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454 
Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332 
investors@morphosys.com